Home LiteratureArticle Details
PMID: 1081373 Published · ppublish English Journal Article

Vestibular reactions associated with minocycline.

Antimicrobial agents and chemotherapy ·Vol. 8 ·No. 4 ·1975-10-00 ·Pages 453-6

Jacobson JA, Daniel B

Abstract

Several recent reports have indicated that minocycline, a drug effective for meningococcal disease prophylaxis, is associated with a high incidence of vestibular side effects. In January 1975, a questionnaire on adverse reactions was completed by all 29 staff members of a North Georgia hospital who had taken minocycline at the recommended dosage after exposure to a suspected meningococcal meningitis case and by 25 age-, sex-, and occupation-matched non-treated controls. In the treated group 86% experienced moderate to severe vestibular symptoms; 84% of the symptomatic persons experienced their onset after one or two doses of 100 mg. Fifty-two percent of the treated staff members stopped taking the medication because of these effects. The symptoms resolved within 48 h after affected persons discontinued the medication. Until the safety of minocycline can be reestablished, rifampin is recommended for meningococcal disease prophylaxis, and alternative drugs are encouraged for other indications.

MeSH Terms
Adult Female Humans Male Meningitis, Meningococcal/prevention & control Minocycline/adverse effects,therapeutic use Surveys and Questionnaires Tetracyclines/adverse effects Vestibule, Labyrinth/drug effects
Chemicals
Tetracyclines Minocycline
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Jacobson J A
Daniel B
References (13)
13 references, click to expand
  1. IN VIVO AND IN VITRO RESISTANCE TO SULFADIAZINE IN STRAINS OF NEISSERIA MENINGITIDIS.
    JAMA. 1963 Oct 12;186:139-41 PMID: 14056528
  2. Alginate-antacid in the reduction of gastro-oesophageal reflux.
    Lancet. 1974 Jan 26;1(7848):109-11 PMID: 4130309
  3. Letter: Minocycline: Possible vestibular side-effects.
    Lancet. 1974 Nov 23;2(7891):1260 PMID: 4139487
  4. Minocycline: Possible vestibular side-effects.
    Lancet. 1974 Sep 28;2(7883):744-6 PMID: 4143012
  5. Seroepidemiology and chemoprophylaxis disease due to sulfonamide-resistant Neisseria meningitidis in a civillian population.
    J Infect Dis. 1974 Sep;130(3):217-24 PMID: 4213375
  6. Eradication of carriage of Neisseria meningitidis in families: a study in Brazil.
    J Infect Dis. 1974 Jun;129(6):644-9 PMID: 4209720
  7. Trends in disease caused by Neisseria meningitidis: 1972 and 1973.
    J Infect Dis. 1974 Aug;130(2):212-4 PMID: 4210454
  8. Field trial of the efficacy of a previously proposed regimen using minocycline and rifampin sequentially for the elimination of meningococci from healthy carriers.
    Am J Epidemiol. 1973 Jun;97(6):394-401 PMID: 4197420
  9. Minocycline in the chemoprophylaxis of meningococcal disease.
    Antimicrob Agents Chemother. 1972 May;1(5):397-402 PMID: 4670480
  10. Rifampin. Levels in serum and saliva and effect on the meningococcal carrier state.
    JAMA. 1970 Nov 9;214(6):1055-9 PMID: 4990906
  11. The effect of minocycline on meningococcal nasopharyngeal carrier state in naval personnel.
    Am J Epidemiol. 1971 May;93(5):337-45 PMID: 4997355
  12. Efficacy of rifampin in treatment of meningococcal carriers.
    N Engl J Med. 1969 Sep 18;281(12):641-5 PMID: 4980025
  13. Effect of rifampin and minocycline on meningococcal carrier rates.
    J Infect Dis. 1971 Aug;124(2):199-205 PMID: 4942060
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
1975-10-00
Pages
453-6
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC429369
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]